Cautious Optimism As Genentech/AC Immune’s Anti-Tau Antibody Slows Cognitive Decline
Next Steps May Depend On Longer-Term Open-Label Data
Semorinemab met only the cognition co-primary endpoint in the Phase II LAURIET trial in mild-to-moderate Alzheimer’s patients and missed all secondary endpoints, but some firsts were achieved in the top-line readout.
